Why Conglomerate Operating Systems Are Stifling Commercial Innovation in Life Sciences

In the life sciences sector, conglomerates like Danaher, Thermo Fisher Scientific, GE HealthCare, and others have excelled at driving internal product innovation and enabling client-side breakthroughs. Their operating models—systems such as the Danaher Business System (DBS) or Thermo Fisher’s Practical Process Improvement (PPI)—have become gold standards for operational excellence. However, these same systems that catalyse product and process innovation are increasingly hampering commercial innovation. Specifically, they are slowing the adoption of AI-driven solutions, modern go-to-market strategies, dynamic pricing models, and customer orchestration capabilities critical for the future of healthcare and life sciences.

The Strength of the Machine: Conglomerate operating systems bring undeniable strengths: relentless focus on continuous improvement, deep-rooted Lean and Six Sigma principles, and operational discipline. These frameworks have been instrumental in:

• Scaling manufacturing precision.
• Improving R&D cycle times.
• Standardising quality across complex portfolios.

Their impact on product excellence and customer enablement has been transformative, particularly in complex verticals such as bio-manufacturing, precision diagnostics, and MedTech innovation.

The Hidden Cost

Yet, this rigid adherence to predefined processes comes at a significant cost when organisations attempt to innovate “front of house.” Commercial teams—sales, marketing, pricing, and customer success—operate in a radically different environment today:

• Buying cycles are increasingly digital, dynamic, and consultative.
• Customers demand value-based outcomes, not just product features.
• AI and data analytics can (and should) rewire account management, sales forecasting, and pricing strategies.

Traditional conglomerate systems prioritise efficiency, control, and standardisation. Commercial innovation, by contrast, requires adaptability, experimentation, and speed. Embedding AI into these legacy operating systems becomes difficult because the systems were never designed to support fluid, feedback-driven commercial dynamics.

Specific Symptoms of the Problem:

1. Slow AI Adoption in Commercial Functions: AI models for customer segmentation, pricing optimisation, and sales enablement remain under-deployed.
2. Rigid Go-to-Market Models: Traditional operating systems like DBS foster linear, stepwise approaches to market engagement—designed for repeatability and efficiency. However, today’s healthcare and life sciences markets resemble a dynamic web of interconnectivity, where customer needs, partnerships, data flows, and procurement pathways constantly shift and overlap. This misalignment between linear GTM processes and a networked market reality hampers cross-sell, up-sell, and bundled solutions, and is further exacerbated by legacy organisational silos.
3. Conservative Pricing Strategies: Despite advances in real-time data analytics, dynamic pricing or outcomes-based contracting is rare. This not only slows competitiveness but directly impacts financial performance. Static pricing models mean organisations often leave significant value on the table—either by underpricing high-value offerings or by failing to capture premium margins aligned with specific customer outcomes. Moreover, slow adoption of dynamic pricing capabilities reduces negotiation power, elongates deal cycles, and prevents sales teams from tailoring value propositions in real-time. In a world where precision pricing and personalised contracting increasingly differentiate leaders from laggards, these conglomerates risk both revenue leakage and strategic irrelevance.
4. Over-Reliance on Traditional Salesforces: Many conglomerates still lean heavily on technical field sales, despite clear signals that buyers prefer digital engagement.
5. Cultural Resistance: Commercial teams are often measured by outdated KPIs aligned to volume-based selling rather than customer lifetime value, agility, or cross-functional collaboration.
   

Comparative Analysis of Commercial Innovation Gaps